Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

BACKGROUND: Carcinoma of unknown primary (CUP) accounts for 3–5% of all adult solid tumors. An extensive search for the anatomic site of origin is often undertaken in an attempt to tailor systemic treatment, but the latter often has limited efficacy – especially in the setting of an initial treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Palma, Norma A., Ali, Siraj M., O'Connor, Jamie, Dutta, Deepa, Wang, Kai, Soman, Salil, Palmer, Gary A., Morosini, Deborah, Ross, Jeffrey S., Lipson, Doron, Stephens, Phil J., Patel, Mayur, Miller, Vincent A., Koutrelakos, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: July, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164090/
https://www.ncbi.nlm.nih.gov/pubmed/25232318
http://dx.doi.org/10.1159/000365326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164090/
https://www.ncbi.nlm.nih.gov/pubmed/25232318
http://dx.doi.org/10.1159/000365326

Ejemplares similares